Corcept Therapeutics Inc
CORT
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
4.9% upsideUndervalued by 4.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.58 Billion |
|---|---|
| Enterprise Value | $8.49 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.95 |
| Beta | 0.5 |
| Outstanding Shares | 104,435,000 |
Return
| Return on Equity | 7.38% |
|---|---|
| Return on Assets | 5.77% |
| Return on Invested Capital | 0.33% |
Valuation & Multiples
| P/E Ratio | 177.58 |
|---|---|
| PEG | -69.97 |
| Price to Sales | 11.41 |
| Price to Book Ratio | 13.31 |
| Enterprise Value to Revenue | 11.05 |
| Enterprise Value to EBIT | 3814.43 |
| Enterprise Value to Net Income | 180 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0773▼ 134.28% |
|---|---|
| Total Calls | 1,027,301▼ 29.26% |
| Total Puts | 2,134,000▼ 57.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.58%▲ 2.62% |
|---|---|
| Total Invested | $3.20B▲ 19.96% |
| Investors Holding | 368▼ 51.00% |
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...
Relevant Senate Committees
Oversees Medicare and Medicaid; these programs are primary payers for high-cost specialty drugs like Korlym, making this committee critical for Corcept’s revenue.
Controls the precise cash flow for the FDA and HHS; its funding decisions directly determine the resources available for drug reviews and medical research.
Directly oversees the FDA and NIH; this committee writes the laws governing drug approval processes, safety standards, and clinical trial requirements.
Oversees intellectual property and patent laws, which are vital to Corcept's ability to protect its proprietary cortisol modulators from generic competition.
Investigates drug pricing and healthcare issues affecting older populations; Corcept’s drugs for Cushing's and metabolic disorders are key targets for pricing scrutiny.